Recce Pharmaceuticals Ltd. announced an Independent Safety Committee approved an increase in dosing to 4,000mg over a fast infusion of 30 minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327). The Company has now dosed 3,000mg at multiple infusion times: 15, 20, 30, 45 minutes, and 1 hour. Dosing has successfully achieved Minimum Inhibitory Concentration (MIC) activity among existing clinical samples.

The Company has identified 30 minutes as the potential optimum infusion time and increased to a higher concentration as per regulatory expectations to investigate R327?s high concentration potential. The efficacy of R327 via IV administration will be made available at the completion of this trial in line with the study protocol. In a parallel clinical program, R327 was applied topically against diabetic foot ulcer infections and recently demonstrated its potential against a broad range of antibiotic-resistant infections.